Allergan to cash in on eyelash stimulant effect of glaucoma drug

Following positive clinical trial results, Allergan, the makers of bimatoprost, are submitting a new drug application (NDA) to the US Food and Drug Administration (FDA), seeking a new indication for the prostaglandin analogue as an eyelash growth stimulant.

Related Content:

ArticlesGlaucoma

ASRS 39th Annual Scientific Meeting prepares to impress in San Antonio, Texas

Bejeweled 17th century eyeglasses up for auction at Sotheby’s London

An eye towards plateau iris and its implications for patients